Dicot broadens the testing of the drug candidate LIB-01: conducts studies of premature ejaculation
Press release: Uppsala, February 5, 2021. The main focus for the potency drug developer Dicot has so far been on studying the effect on erectile dysfunction in its drug candidate LIB-01. In accordance with the company's overall strategy, testing is now being broadened. Therefore, studies of premature ejaculation have started together with the world-leading contract research organisation that has participated in preclinical testing of several renowned compounds in this field.Dicot's goal for its drug candidate LIB-01 (formerly Libiguin) is to be the leading treatment for erectile dysfunction